RxDoctor Payments Data

James Matchison, MD

Interventional Cardiology · Torrance, CANPI 1629275631

Payments from drug & device makers

$33,340in general payments, 2019–2025

Across 510 payments — averaging $65.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$16K
  • Abiomed$7K
  • Boston Scientific$2K
  • Shockwave Medical, Inc$2K
  • Philips North America LLC$919
  • Medtronic$860
  • plus $4K from 28 others

What the payments were for

  • Consulting fees$12,50037%
  • Speaking & faculty fees$2,7508%
  • Travel & lodging$2,6368%
  • Food & beverage$15,44546%
  • Education$90%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$33,340 in reported general payments places this provider in the 70th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$225,142
Medicare patients
969
Services billed
3,093

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban473$553,653
EntrestoSacubitril/Valsartan95$127,553
Repatha SureclickEvolocumab109$90,318
XareltoRivaroxaban59$69,309
FarxigaDapagliflozin Propanediol47$47,822
JardianceEmpagliflozin26$35,779
Praluent PenAlirocumab22$16,057
BrilintaTicagrelor18$14,819
VascepaIcosapent Ethyl15$9,738
Nebivolol Hcl88$6,456
Dabigatran EtexilateDabigatran Etexilate Mesylate21$5,394
Metoprolol Succinate280$4,828
Ranolazine ErRanolazine18$4,420
Atorvastatin Calcium424$4,328
ClopidogrelClopidogrel Bisulfate270$3,857

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$372$553,653473 claims
NovartisEntresto$497$127,55395 claims
Johnson & JohnsonXarelto$377$69,30959 claims
AstraZenecaFarxiga, Brilinta$50$62,64165 claims
Boehringer IngelheimJardiance$16$35,77926 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in Torrance

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →